Department of Surgical Oncology, Cancer Institute (WIA), Chennai, TN, India.
Department of Endocrinology and Diabetology, Dr. Rela Institute and Medical Centre, Chennai, TN, India.
Urol Oncol. 2023 May;41(5):258.e1-258.e6. doi: 10.1016/j.urolonc.2023.02.008. Epub 2023 Apr 3.
Persistent Mullerian duct syndrome (PMDS) is a rare disorder of sexual differentiation resulting from aberrations in the Mullerian inhibiting factor (MIF) pathway, with consequent failure of regression of fetal Mullerian duct. The concomitant association of undescended testis increases the likelihood of developing testicular tumors in these patients. Due to its rarity, clinic-pathologic and treatment outcome data on testicular cancer in PMDS is sparse. We present our institutional experience and review published literature on testicular cancer in PMDS.
We retrospectively queried our institutional testicular cancer database for all patients with a diagnosis of testicular cancer and PMDS, between January 1980 and January 2022. Additionally, a Medline/PubMed search was performed for English language articles published during the same time period. Data on pertinent clinical, radiologic, and pathologic disease characteristics were abstracted, in addition to treatment received and outcomes.
Of 637 patients treated for testicular tumors during the specified time period in our institution, 4 patients had a concomitant diagnosis of PMDS. Testicular tumor was pathologically confirmed as seminoma in 3, 1 had mixed germ cell tumor. All patients in our series presented with stage 2B or higher disease and required chemotherapy, either in the neoadjuvant or adjuvant setting, in addition to surgery. With a mean follow up of 67 months, all patients were disease free. Medline/PubMed search retrieved 44 articles (49 patients) of testicular tumors associated with PMDS, with majority (59%) presenting with a large abdominal mass. Only 5 cases (10%) had a preceding history of appropriately managed cryptorchidism.
Testicular cancer in PMDS usually presents in adults with advanced stage disease resulting from neglected or inadequate management of cryptorchidism. Appropriate management of cryptorchidism in childhood is likely to decrease malignant degeneration, if not, enable early-stage diagnosis.
持续性 Müllerian 管发育不全(PMDS)是一种罕见的性分化障碍,源于 Müllerian 抑制因子(MIF)途径的异常,导致胎儿 Müllerian 管退化失败。同时伴有隐睾会增加这些患者发生睾丸肿瘤的可能性。由于其罕见性,关于 PMDS 中睾丸癌的临床病理和治疗结果数据很少。我们介绍了我们机构的经验,并回顾了 PMDS 中睾丸癌的已发表文献。
我们回顾性地查询了我们机构的睾丸癌数据库,以确定所有在 1980 年 1 月至 2022 年 1 月期间诊断为睾丸癌和 PMDS 的患者。此外,还在同一时期内进行了 Medline/PubMed 搜索,以获取英文文章。提取了与相关临床、放射学和病理疾病特征有关的数据,以及所接受的治疗和结果。
在我们机构指定时间段内,有 637 名患者接受了睾丸肿瘤治疗,其中 4 名患者同时诊断为 PMDS。睾丸肿瘤在病理上确认为 3 例精原细胞瘤,1 例混合性生殖细胞肿瘤。我们系列中的所有患者均处于 2B 期或更高分期,需要化疗,无论是新辅助化疗还是辅助化疗,此外还需要手术。在平均随访 67 个月后,所有患者均无疾病。Medline/PubMed 搜索共检索到 44 篇(49 例)与 PMDS 相关的睾丸肿瘤文章,其中大部分(59%)表现为巨大的腹部肿块。只有 5 例(10%)有适当治疗的隐睾病史。
PMDS 中的睾丸癌通常在成年人中出现,由于隐睾的忽视或处理不当,导致疾病处于晚期。儿童时期适当管理隐睾可能会减少恶性转化,如果不能早期诊断,则可以实现早期诊断。